Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches

Reuters

05-27

Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches

Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluebird Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250527213734) on May 27, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538660334"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538660334\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538660334?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538660334","market":"nz","top_or_hot":-1,"title":"Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluebird Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250527213734) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-27 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluebird Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250527213734) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL2pX4sg:1","article_id":"2538660334","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538660334","pubTimestamp":1748349023,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"随着凯雷和SK Capital收购截止日期的临近，蓝鸟生物敦促股东投标股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLUE":0.9},"content_text":"Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches\n    \n\n        Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluebird Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250527213734) on May 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}